In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KuDOS/Novacea: Pooling Biotech Resources

Executive Summary

KuDOS Pharmaceuticals' first out-licensing deal appears disappointing: the UK biotech has neither signed an established cancer player nor secured a significant upfront fee for its potentially first-in-class cancer compound, in a hot area of research. But the point of the deal is not to bolster KuDOS' cash coffers, rather, to combine the resources of two biotechs to investigate the drug's potential in a broader range of indications than either company could do alone.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel